UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/595,977	06/14/2007	Mark Ashby	1001.2219102	1136
	7590 03/30/200 SEAGER & TUFTE, L	EXAMINER		
1221 NICOLLE		MASHACK, MARK F		
SUITE 800 MINNEAPOLI	S, MN 55403-2420	ART UNIT	PAPER NUMBER	
			3773	
			MAIL DATE	DELIVERY MODE
			03/30/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.		Applicant(s)	
	10/595,977	ASHBY ET AL.	
	Examiner	Art Unit	
	MARK MASHACK	3773	

	MARK MASHACK	3773	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress
THE REPLY FILED 18 March 2009 FAILS TO PLACE THIS AP	PLICATION IN CONDITION FOR	ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Apper for Continued Examination (RCE) in compliance with 37 C periods:	replies: (1) an amendment, affidavit eal (with appeal fee) in compliance	t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this Ar no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (I MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f	dvisory Action, or (2) the date set forth inter than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE ().	g date of the final rejection FIRST REPLY WAS FIL	n. .ED WITHIN TWO
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the s set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount of hortened statutory period for reply origin	of the fee. The appropria nally set in the final Offic	te extension fee e action; or (2) as
 The Notice of Appeal was filed on A brief in complifiling the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed with AMENDMENTS 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
3. The proposed amendment(s) filed after a final rejection, be (a) They raise new issues that would require further core (b) They raise the issue of new matter (see NOTE below (c) They are not deemed to place the application in bette appeal; and/or (d) They present additional claims without canceling a content of the second	nsideration and/or search (see NOT w); ter form for appeal by materially rec corresponding number of finally reje	E below); ducing or simplifying th	
NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.1.4. The amendments are not in compliance with 37 CFR 1.12.5. Applicant's reply has overcome the following rejection(s): Newly proposed or amended claim(s) would be all	21. See attached Notice of Non-Cor		,
non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE		l be entered and an ex	xplanation of
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 			
 The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary The affidavit or other evidence is entered. An explanation 	vercome <u>all</u> rejections under appea and was not earlier presented. Se	ıl and/or appellant fails ee 37 CFR 41.33(d)(1)	s to provide a
REQUEST FOR RECONSIDERATION/OTHER 11. The request for reconsideration has been considered but		•	
See Continuation Sheet. 12. ☐ Note the attached Information Disclosure Statement(s). (13. ☐ Other:	PTO/SB/08) Paper No(s)		
/(Jackie) Tan-Uyen T. Ho/ Supervisory Patent Examiner, Art Unit 3773			

Continuation of 3. NOTE: The claim limitation "releasing the flexible plug intravascularly at the blood vessel puncture site" requires additional search and consideration.

Continuation of 11. does NOT place the application in condition for allowance because: Applicant argues that Hannam et al. does not disclose "that spring member 62 is coupled to the hemostatic material opposite the flexible plug". Examiner respectfully disagrees. The function of the spring member 62 is to "retain the anchor member 30 in a desired position adjacent to the wall of the artery" (Column 11, Lines 16-19). The function of the anchor member 30 is "to prevent the fibrin and thrombin materials [hemostatic material] from entering the blood vessel of the patient" (Column 12, Lines 6-10). Therefore the spring member 62 is coupled to the hemostatic material opposite the flexible plug relative to the blood vessel. Applicant argues that "plunger 38 does not couple a hemostatic body to the flexible disk at all" and "is clearly not positioned within the wall of the blood vessel puncture site". Plunger pushes the anchor member 30 out of the distal outlet 34 into the blood vessel intravascularly (FIG 3-4 and Column 10, Lines 31-33) and ejects the hemostatic material into the puncture sight (FIG 10-12 and Column 13, Lines 26-31). The hemostatic body and the flexible disk would not be coupled without the plunger and the plunger is positioned within the wall of the blood vessel puncture site for both of its functions.